Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 18/20 | 0.87 |
| ▸ | JAK2 | O60674 | 5/20 | 0.84 |
| ▸ | JAK1 | P23458 | 3/20 | 0.80 |
| ▸ | STAT3 | P40763 | 1/20 | 0.80 |
| ▸ | STAT1 | P42224 | 1/20 | 0.80 |
| ▸ | JAK3 | P52333 | 1/20 | 0.80 |
| ▸ | BMPR2 | Q13873 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31369028 | 1.00 | TYK2 (0.87) | TYK2JAK2JAK1STAT3STAT1 | |
| SCHEMBL24930118 | 0.94 | TYK2 (0.77) | TYK2JAK2JAK1STAT3STAT1 | |
| SCHEMBL22647341 | 0.93 | TYK2 (1.00) | TYK2JAK2JAK1STAT3STAT1 | |
| SCHEMBL22263494 | 0.93 | TYK2 (0.87) | TYK2JAK2JAK1STAT3STAT1 | |
| SCHEMBL23096153 | 0.93 | TYK2 (0.87) | TYK2JAK2JAK1STAT3STAT1 | |
| SCHEMBL32691810 | 0.93 | TYK2 (0.87) | TYK2JAK2JAK1STAT3STAT1 | |
| SCHEMBL15698602 | 0.92 | TYK2 (0.85) | TYK2JAK2JAK1STAT3STAT1 | |
| SCHEMBL29122675 | 0.92 | TYK2 (0.85) | TYK2JAK2JAK1STAT3STAT1 | |
| SCHEMBL30065992 | 0.92 | TYK2 (0.85) | TYK2JAK2JAK1STAT3STAT1 | |
| SCHEMBL22280388 | 0.91 | TYK2 (0.84) | TYK2JAK2JAK1STAT3STAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731956-B2 | Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors | ALUMIS INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731956-B2 | Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors | ALUMIS INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230021554-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC. | 2023-01-26 | — | — | US | disclosed |
| US-20230023761-A1 | SUBSTITUTED PYRIDINES AS TYK2 INHIBITORS | ALUMIS INC. | 2023-01-26 | — | — | US | disclosed |
| CN-113563309-A | Pyridine derivative and preparation method and application thereof | 浙江海正药业股份有限公司 | 2021-10-29 | — | — | CN | disclosed |
| US-11053219-B2 | Substituted pyridines as TYK2 inhibitors | ESKER THERAPEUTICS, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200354338-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC. | 2020-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053219-B2 | Substituted pyridines as TYK2 inhibitors | TYK2, JAK1, PDXK | TYK2 1/4885JAK2 5/4885JAK1 2/4885 |
| US-20230021554-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK1, JAK2 | TYK2 1/4885JAK2 3/4885JAK1 2/4885 |
| US-20230023761-A1 | SUBSTITUTED PYRIDINES AS TYK2 INHIBITORS | TYK2, JAK1, PDXK | TYK2 1/4885JAK2 4/4885JAK1 2/4885 |
| US-20200354338-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK1, JAK2 | TYK2 1/4885JAK2 3/4885JAK1 2/4885 |
| US-11731956-B2 | Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors | TYK2, JAK1, JAK3 | TYK2 1/4885JAK2 4/4885JAK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.